Efficacy and Safety of LCZ696 Compared to Olmesartan in Essential Hypertensive Patients Not Responsive to Olmesartan

NCT01876368 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

376

Enrollment

INDUSTRY

Sponsor class

Conditions

Hypertension

Interventions

DRUG: LCZ696
DRUG: Olmesartan
DRUG: Placebo of LCZ696
DRUG: Placebo of Olmesartan

Sponsor

Novartis Pharmaceuticals